BraiN20®: A paradigm shift in Acute Ischemic Stroke (AIS) patient management

Acute Ischemic Stroke (AIS) represents 85% of strokes and is the 2nd leading cause of death and the leading cause of disability worldwide.

Today, AIS patient management lies on imaging tools (multimodal CT/MRI) and scores to select patients for Endovascular treatment (EVT) the gold standard. Still, its efficacy is limited to 46% due to the lack of tools to guide decision-making.

BraiN20 is a non-invasive medical device class IIb that provides real-time monitoring of AIS patients brain viability, thereby predicting who will benefit from EVT.

Time is Brain has the exclusive right to the IPR of a neurophysiological biomarker: N20, a SEP and surrogate of cerebral blood flow.

TiB aims to implement the clinical trials to validate BraiN20, acquire CE-Mark and FDA clearance, and bring it to market.

By providing real-time and continuous monitoring of brain viability, BraiN20 will accelerate stroke management and predict EVT outcome and offer tailored care for each patient.